Unit 2, 22nd Floor, Tower 6789, 6789 Ayala Avenue, Makati City

+63 28887 5160

HCP Portal Login
a

EISAI INVESTS IN C2N TO SUPPORT SIMPLIFYING THE DIAGNOSIS OF EARLY ALZHEIMER’S DISEASE TO BETTER SERVE PATIENTS

For Print (PDF)

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that its U.S. subsidiary Eisai Inc. has decided to invest up to 15 million USD in C2N Diagnostics LLC (Headquarters: St. Louis, Missouri, the United States “C2N”) to support C2N’s efforts to expand the availability, accessibility, affordability and utilization of blood-based tests for the diagnosis of Alzheimer’s disease (AD) in the U.S. This investment is in addition to the collaboration with C2N announced in August 2022 regarding the use of blood-based assays in the diagnosis of people living with dementia in clinical practice in the U.S.

The presence of amyloid β (Aβ), a component of AD pathology, is currently confirmed using advanced diagnostic techniques such as positron emission tomography (PET) or by tests that require the collection of cerebrospinal fluid (CSF). By investing in C2N, Eisai seeks to support efforts to advance blood-based Aβ diagnostics that are accurate and affordable, providing new options for confirming the presence of Aβ.

“The field of highly accurate blood-based diagnostics is rapidly advancing and expanding,” said Keisuke Naito, Global Alzheimer’s Disease Officer, Senior Vice President, Eisai. “Given the expense and capacity limitations of PET and CSF tests, Eisai is working to support the dementia ecosystem’s growth. The availability of more affordable and minimally invasive diagnostic tools helps support broad access for the management of Alzheimer’s disease.”

An estimated 6.7 million people in the U.S. are living with Alzheimer’s dementia.1 Clinical symptoms alone cannot provide accurate diagnosis. Identifying patients through accurate and simple blood-based testing may lead to more efficient diagnoses, expanded treatment opportunities and reduced medical and care costs, thereby simplifying and accelerating earlier treatment, when appropriate. Importantly, blood-based tests could also support improved care for people in underserved communities and areas where access to amyloid PET and CSF testing are not a viable option.

As a pioneer in the AD field and an hhceco company, Eisai is strongly committed to supporting the development of an environment that includes the blood-based diagnosis of AD. Using multiple approaches, Eisai collaborates with several diagnostic companies and with local governments to expand the dementia ecosystem. This investment and Eisai’s collaboration with C2N are examples of such activities, through which we seek to provide and support solutions that can help relieve the anxieties of people living with AD, their families and care partners.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Eisai Inc. (U.S.)
Libby Holman
+ 1-201-753-1945
Libby_Holman@eisai.com

 

[Notes to editors]

1.  About C₂N Diagnostics, LLC

C2N Diagnostics (“C2N”) is a specialty diagnostics company with a vision to bring Clarity Through Innovation®. C2N strives to provide exceptional clinical laboratory services and advanced diagnostic solutions in the field of brain health. C2N’s high-resolution mass spectrometry-based biomarker services and products are used for: clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health.

C2N assays have been used in over 150 Alzheimer’s disease and other research studies throughout the U.S. and the world. This includes landmark treatment and prevention trials involving disease-modifying therapies (DMTs) that are changing the trajectory of Alzheimer’s disease. C2N has ongoing collaborations with multi-national pharmaceutical and biotech companies, leading academic institutions, National Institute on Aging, Alzheimer’s Association, and other non-profits and consortiums. Over 15,000 Precivity™-related biomarker measures have been reported through peer-reviewed publications, with many more manuscripts currently under review. For more information visit www.C2N.com.

1. https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf

Our Values

Values are an integral part of our foundation. With every decision, we ensure that we follow:

Integrity

Integrity is the living up to legal, moral and ethical principles in the conduct of HI-Eisai Pharmaceutical Inc. business. It means that each employee embodies the value of integrity, and therefore represents the company in honesty and rectitude in all the ways they do their work.

It is expected that each employee would make decisions guided by good judgement, not just for one‘s self, but for HI-Eisai as the company. An employee who acts with integrity ensures that he has understanding of the principles by which the company operates, and in situations where he lacks clarity, will actively seek guidance.

Respect

The company is committed to ensure that it maintains a safe, inclusive, and healthy working environment that promotes productivity among employees. All employees are expected to show respect to fellow employees, customers, and patients, regardless of differences in gender, culture, backgrounds, and beliefs. Leaders in the organization are likewise expected to promote inclusivity with their teams, and shall not tolerate any discriminatory and offensive actions.

Accountability

Accountability at work means assuming responsibility for the business outcome and how that is achieved. It means that every employee, in whichever position, are equally responsible for the decisions and actions they make for the company. It is likewise, the responsibility of each employee to report, any knowledge of misconduct or potential violation to the company‘s rules and regulations.

Patient-Centric

At the heart of the company‘s operation are the patients. This means that every decision to be made, considers the potential impact and benefit to the patients. As such, the company commits itself in ensuring that business objectives align with its principle of human health care or hhc. The programs created and implemented are based on how well they could contribute to improving patients‘ lives.

For field-based employees, being patient-centric means that the focus of engagements with customers are on understanding patient needs as well as providing these stakeholders with comprehensive information on how HI-Eisai‘s products can support their patients goals.

For each employee, being patient-centric means taking on their responsibilities with care and consideration on how it impacts the patients experience, be it by making relevant information readily available for the doctors; or by ensuring access and availability to the medicines we offer.

Excellence

As a patient-centric company, we define Excellence by the outstanding quality of our work to improve patients‘ lives. Each employee is expected to consistently demonstrate work ethics that align to our values, policies, and our desire to provide above standard service. The company is committed in ensuring that all actions are in compliance with legal requirements.

Being excellent means that every employee passionately strives to be better and participates in the company‘s initiatives to develop their members in terms of knowledge, skills, and behavior, which will support a continuously improving, responsible and performance-driven workforce.

Our Vision

To be a successful and sustainable business in the Philippines by driving innovation and providing solutions to address unmet healthcare needs fueled by high-performing employees who deliver meaningful value and experience to patients and their families.

Our Mission

We give first thought to patients and their families, and to increasing the benefits health care provides.

Unit 2, 22nd Floor, Tower 6789, 6789 Ayala Avenue, Makati City

+63 28887 5160